Purnima Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 2.43 M
- Company Age 37 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
About Purnima Pharmaceuticals
Purnima Pharmaceuticals Private Limited (PPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 April 1987 and has a history of 37 years and ten months. Its registered office is in Jaipur, Rajasthan.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.43 M.
The company currently has active open charges totaling ₹1.00 M.
Mulji Kalinani, Purnima Kalinani, Lalitaben Kalinani, and Four other members serve as directors at the Company.
Company Details
- Location Jaipur, Rajasthan
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232RJ1987PTC004915
- Company No.
004915
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Apr 1987
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Purnima Pharmaceuticals?
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Purnima Kalinani  | Director | 06-Apr-1987 | Current |
| Mulji Kalinani | Director | 06-Apr-1987 | Current |
| Lalitaben Kalinani | Director | 06-Apr-1987 | Current |
| Meeta Kalinani | Director | 20-Mar-2015 | Current |
| Mamta Kalinani | Director | 20-Mar-2015 | Current |
| Sanjay Kalinani | Director | 20-Mar-2015 | Current |
Financial Performance of Purnima Pharmaceuticals.
Purnima Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Purnima Pharmaceuticals?
In 2017, Purnima Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of Baroda : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Apr 1990 | Bank Of Baroda | ₹1.00 M | Open |
How Many Employees Work at Purnima Pharmaceuticals?
Purnima Pharmaceuticals has a workforce of 14 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Purnima Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Purnima Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.